Nevertheless, these agents demonstrate efficacy exclusively in NSCLC with KRAS G12C mutations; moreover, their overall effectiveness remains unsatisfactory, and drug resistance occurs at 6–8 months (5–7). Here, KRAS is linked to non-small cell lung carcinoma.